Figure 3From: Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer Analysis of recurrence by risk category in stage I NSCLC. (A) Recurrence-free survival according to CDK1SA-based risk with a cut-off value of 12.6 maU/eU. (B) Recurrence-free survival according to CDK2SA-based risk with a cut-off value of 222 maU/eU.Back to article page